Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and raises the price target from $8 to $11.
July 13, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Recursion Pharmaceuticals and raises the price target from $8 to $11.
The news of Morgan Stanley maintaining an Equal-Weight rating on Recursion Pharmaceuticals and raising the price target from $8 to $11 is directly related to the company. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100